IRIS
DE LUCA, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.433
EU - Europa 15.829
AS - Asia 2.883
SA - Sud America 107
AF - Africa 45
OC - Oceania 36
Continente sconosciuto - Info sul continente non disponibili 16
Totale 38.349
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.361
GB - Regno Unito 5.765
IE - Irlanda 2.471
IT - Italia 2.227
UA - Ucraina 1.861
CN - Cina 1.796
RU - Federazione Russa 901
SE - Svezia 853
FR - Francia 848
SG - Singapore 559
DE - Germania 369
VN - Vietnam 239
FI - Finlandia 229
ES - Italia 81
BR - Brasile 79
TR - Turchia 61
BE - Belgio 59
IN - India 58
CA - Canada 50
IR - Iran 36
AU - Australia 29
NL - Olanda 29
HK - Hong Kong 25
AT - Austria 23
EU - Europa 16
PL - Polonia 15
ZA - Sudafrica 15
CZ - Repubblica Ceca 13
GR - Grecia 13
JP - Giappone 13
ID - Indonesia 12
CO - Colombia 11
PK - Pakistan 10
PH - Filippine 9
SK - Slovacchia (Repubblica Slovacca) 9
MX - Messico 8
CH - Svizzera 7
CI - Costa d'Avorio 7
KR - Corea 7
AR - Argentina 6
BD - Bangladesh 6
HU - Ungheria 6
IL - Israele 6
LU - Lussemburgo 6
NZ - Nuova Zelanda 6
PA - Panama 6
PT - Portogallo 6
BG - Bulgaria 5
IQ - Iraq 5
TH - Thailandia 5
EE - Estonia 4
JM - Giamaica 4
LB - Libano 4
LV - Lettonia 4
MN - Mongolia 4
NO - Norvegia 4
BW - Botswana 3
CL - Cile 3
DK - Danimarca 3
EG - Egitto 3
ET - Etiopia 3
IM - Isola di Man 3
KG - Kirghizistan 3
LT - Lituania 3
NG - Nigeria 3
PE - Perù 3
RO - Romania 3
SA - Arabia Saudita 3
TW - Taiwan 3
UG - Uganda 3
AE - Emirati Arabi Uniti 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GH - Ghana 2
KZ - Kazakistan 2
LK - Sri Lanka 2
SN - Senegal 2
UY - Uruguay 2
AL - Albania 1
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
CR - Costa Rica 1
CY - Cipro 1
EC - Ecuador 1
JO - Giordania 1
KH - Cambogia 1
KW - Kuwait 1
MA - Marocco 1
MD - Moldavia 1
MK - Macedonia 1
MT - Malta 1
MY - Malesia 1
NC - Nuova Caledonia 1
NP - Nepal 1
OM - Oman 1
PS - Palestinian Territory 1
PY - Paraguay 1
Totale 38.342
Salva come PNG Salva come JPEG
Città #
Southend 5.332
Fairfield 2.929
Dublin 2.455
Chandler 1.811
Ashburn 1.548
Jacksonville 1.540
Woodbridge 1.483
Seattle 1.159
Wilmington 1.146
Cambridge 1.026
Houston 1.008
Ann Arbor 649
Santa Clara 617
Menlo Park 511
Princeton 497
Nanjing 459
Siena 424
Singapore 367
Boardman 273
Beijing 268
Dong Ket 229
San Diego 161
Milan 148
Nanchang 147
Helsinki 145
Rome 136
Shenyang 134
Dearborn 115
New York 108
Moscow 89
Tianjin 88
Hebei 86
Changsha 80
San Mateo 74
Jiaxing 67
London 63
Málaga 63
Brussels 54
Shanghai 54
Bologna 52
Munich 50
Kunming 49
Jinan 47
Ningbo 47
Norwalk 47
Zhengzhou 46
Florence 45
Izmir 44
Turin 39
Taizhou 34
Guangzhou 32
Toronto 32
Lancaster 31
San Francisco 31
Falls Church 30
Naples 26
Hefei 25
Los Angeles 25
Genoa 23
Redwood City 22
Vienna 21
Düsseldorf 20
Hangzhou 20
Phoenix 20
Catania 18
Melbourne 18
Padova 18
Chiswick 17
Frankfurt am Main 17
Nottingham 16
Tappahannock 15
Washington 15
Kilburn 14
Lappeenranta 14
Dallas 13
Fremont 13
Hounslow 13
Karaj 13
Lanzhou 13
Bari 12
Changchun 11
New Orleans 11
Horsham 10
Madrid 10
Mestre 10
Tehran 10
Chicago 9
Coventry 9
Fuzhou 9
Kowloon 9
Perugia 9
Tokyo 9
Falkenstein 8
Groningen 8
Palermo 8
Parma 8
Abidjan 7
Bratislava 7
Brno 7
Espoo 7
Totale 28.816
Salva come PNG Salva come JPEG
Nome #
Utilizzo di dalbavancina nella terapia delle infezioni osteoarticolari 919
Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: Implications for the activity of next-line regimens from a longitudinal study in Mozambique 552
Meningoencefalite da Listeria e sindrome di Miller-Fisher: un’inusuale associazione 462
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 457
Staphylococcus aureus vaccine preclinical and clinical development: current state of the art 409
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study 353
A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen 347
ERITEMA NODOSO RECIDIVANTE E PERSISTENTE REPLICA DI EPSTEIN-BARR VIRUS 277
Listeria meningoencephalitis and anti-GQ1b antibody syndrome 266
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe 262
UTILIZZO DI MILTEFOSINA IN PAZIENTE CON LEISHMANIOSI MUCOSA ED INFEZIONE DA HIV 246
"EFFICACY AND SAFETY OF 2-DRUG COMBINATION ANTIRETROVIRAL THERAPY IN CLINICAL PRACTICE: RESULTS FROM A SINGLE CENTER STUDY" 244
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 223
Paediatric obstructive sleep apnoea syndrome (OSAS) is associated with tonsil colonisation by Streptococcus pyogenes 211
Non-granulomatous cerebellar infection by Acanthamoeba spp. in an immunocompetent host 203
Virological and Immunological Response to Antiretroviral Regimens Containing Maraviroc in HIV Type 1-Infected Patients in Clinical Practice: Role of Different Tropism Testing Results and of Concomitant Treatments 202
Clinical and MRI improvement in a case of progressive multifocal leukoencephalopathy 190
Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor 190
Evolution of macrolide resistance in streptococcus pyogenes over 14 years in an area of central Italy 190
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 189
Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score 187
HCMV infection in renal transplant recipients: a retrospective cohort study 187
Pediatric spinal epidural abscess in an immunocompetent host without risk factors: Case report and review of the literature 187
Impact of transmitted drug resistance in naïve-patients starting 2 NRTI plus a boosted protease-inhibitor (PI) or integrase-inhibitor (INSTI). 186
Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals 186
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 185
First report of spondylodiscitis due to vancomycin heteroresistant Staphylococcus capitis in immunocompetent host 182
Case Report: Persistent strongyloidiasis complicated by recurrent meningitis in an HTLV seropositive Peruvian migrant resettled in Italy 181
Sieroprevalenza di HEV in donatori di sangue e pazienti trapiantati di rene nella provincia di Siena. 181
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine 179
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort 176
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 175
Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients 174
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors 174
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 174
Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: A cohort study 173
Nuovi approci diagnostici nelle infezioni pneumococciche: possibile ruolo della Real-time PCR e dei biomarcatori 173
Seroprevalence of hepatitis E virus (HEV) infection in blood donors and renal transplant recipients: a retrospective study from central Italy [Sieroprevalenza dell’infezione da virus dell’epatite E (HEV) in donatori di sangue e pazienti trapiantati di rene: Uno studio retrospettivo dal centro Italia] 170
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 169
Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR. 168
Un caso di “insolita” spondilodiscite da Staphylococcus capitis 168
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort 165
Strategie di vaccinazione anti-pneumococcica nel paziente adulto HIV-positivo: confronto fra vaccino coniugato 13-valente e vaccino polisaccaridico 23-valente 163
Un rarissimo caso di infestazione parassitaria cerebellare da Acanthamoeba spp. In soggetto immunocompetente: primo caso in Italia. 162
Prevalence of M75 Streptococcus Pyogenes strains harboring slaa gene in patients affected by pediatric obstructive sleep apnea syndrome in Central Italy 161
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 158
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 157
High burden of transmitted HIV-1 drug resistance in Italian patients carrying F1 subtype 154
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 153
A novel methodology for large-scale phylogeny partition 151
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study 151
FIBRILLO-FLUTTER IN ASSENZA DI SEGNI DI MIOCARDITE IN CORSO DI INFEZIONE DA EBV 149
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 149
Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response 149
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 149
Gastroenteritis and Intractable Diarrhea in Newborns 148
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 148
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study 146
MIASI CAVITARIA A LOCALIZZAZIONE NASALE DA OESTRUS OVIS: UN CASO CLINICO 145
European guidelines on the clinical management of HIV-1 tropism testing 145
Kaposi Sarcoma Incidence and Survival Among HIV-Infected Homosexual Men After HIV Seroconversion 143
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study 143
Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy 140
Phylogenetic analysis provides evidence of interactions between Italian heterosexual and South American homosexual males as the main source of national HIV-1 subtype C epidemics 140
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 140
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients – evidence from a large observational cohort 140
Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load 139
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 139
Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy 139
Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings 138
null 135
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 134
Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non-AIDS-Defining Events in a Large Cohort of HIV-Infected Patients 134
Evoluzione ed efficace controllo di un vasto focolaio epidemico nosocomiale da Klebsiella pneumoniae produttrice di carbapenemasi in un’area Neurochirurgica: lezioni apprese. 133
Risposta immunitaria a lungo termine dopo vaccinazione antipneumococcica con vaccino coniugato 13-valente o vaccino polisaccaridico 23-valente in adulti HIV positivi 133
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 133
Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009 132
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients 132
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons 132
null 131
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study 131
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 131
null 129
AIDS-associated cerebral toxoplasmosis: an update on diagnosis and treatment. 129
Local and global spatio-temporal dynamics of HIV-1 subtype F1 129
Valutazione della risposta al test IGRA in pazienti pediatrici contatto di TBC o con sospetto clinico di infezione attiva 129
PATOGENI COLONIZZANTI IL NASOFARINGE DI SOGGETTI HIV POSITIVI E HIV NEGATIVI 128
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 128
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 127
Analisi retrospettiva su infezioni invasive e non invasive da batteri Gram negativi non fermentanti in pazienti ospedalizzati 127
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 127
Impact of resistance mutations on virological efficacy of DTG-based maintenance two-drug regimens: a cohort study 126
Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe 125
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. 124
Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in sub-Saharan Africa 123
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients 123
Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort 123
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 123
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure 122
Compartimentalizzazione di HCMV: mancata appropiatezza della sola DNAemia nella diagnosi e nella terapia di una polmonite da HCMV post-trapianto polmonare 121
Totale 18.285
Salva come PNG Salva come JPEG
Categoria #
all - tutte 122.662
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 122.662
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.146 0 0 0 0 0 675 979 1.225 794 749 214 510
2020/20215.952 220 862 201 568 463 640 327 926 319 620 250 556
2021/20223.691 252 482 144 287 141 171 174 188 215 438 355 844
2022/20235.838 378 315 599 906 686 1.293 78 471 630 143 176 163
2023/20243.788 203 125 293 150 153 877 1.230 133 27 127 164 306
2024/20252.885 246 505 619 432 723 360 0 0 0 0 0 0
Totale 39.278